An FDA advisory panel votes 13-2 to recommend that the agency approve Aegerion's (AEGR +5%)...


An FDA advisory panel votes 13-2 to recommend that the agency approve Aegerion's (AEGR +5%) lomitapide drug for treating very high cholestoral in patients with a rare genetic disease called homozygous familial hypercholesterolemia, which can lead to early death. The FDA is due to decide by the end of December.  (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs